Q1 EPS Estimates for Spyre Therapeutics Decreased by Wedbush

Spyre Therapeutics, Inc. (NASDAQ:SYRE) – Analysts at Wedbush cut their Q1 2025 EPS estimates for Spyre Therapeutics in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.86) for the quarter, down from their previous forecast of ($0.84). Wedbush currently has a “Outperform” rating and a $45.00 target price on the stock. The consensus estimate for Spyre Therapeutics’ current full-year earnings is ($4.89) per share. Wedbush also issued estimates for Spyre Therapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.15) EPS, FY2026 earnings at ($2.83) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.98) EPS.

A number of other research analysts also recently weighed in on the company. Guggenheim lifted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the company a “buy” rating in a report on Friday, October 25th. Robert W. Baird lifted their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Spyre Therapeutics has an average rating of “Buy” and an average target price of $48.57.

Spyre Therapeutics Stock Performance

NASDAQ SYRE opened at $29.20 on Friday. The firm’s 50 day moving average price is $31.34 and its two-hundred day moving average price is $30.40. Spyre Therapeutics has a twelve month low of $8.75 and a twelve month high of $47.97. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -3.91 and a beta of 2.90.

Institutional Investors Weigh In On Spyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC increased its holdings in Spyre Therapeutics by 1.5% in the third quarter. FMR LLC now owns 7,623,881 shares of the company’s stock worth $224,218,000 after buying an additional 115,898 shares during the last quarter. Perceptive Advisors LLC grew its position in Spyre Therapeutics by 18.6% in the second quarter. Perceptive Advisors LLC now owns 3,031,018 shares of the company’s stock worth $71,259,000 after acquiring an additional 474,339 shares in the last quarter. Avoro Capital Advisors LLC acquired a new position in shares of Spyre Therapeutics during the 2nd quarter worth $43,238,000. State Street Corp raised its holdings in shares of Spyre Therapeutics by 9.4% during the 3rd quarter. State Street Corp now owns 1,541,555 shares of the company’s stock valued at $45,337,000 after purchasing an additional 131,896 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Spyre Therapeutics by 89.4% in the 3rd quarter. Wellington Management Group LLP now owns 1,507,200 shares of the company’s stock valued at $44,327,000 after purchasing an additional 711,254 shares during the last quarter. 80.39% of the stock is owned by hedge funds and other institutional investors.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).